title: [Cooperative study of surgical adjuvant chemotherapy of colorectal carcinoma (second study): 3-year survival after surgery of non-curatively resected patients. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
abstract: A prospective randomized study was carried out to evaluate the efficacy of surgical adjuvant chemotherapy for non-curatively resected colorectal carcinoma patients as a collaborative study at 428 institutes in Japan from Jan., 1984 to Dec., 1985. A total of 1,138 patients were entered in this study. All patients were divided according to disease location (colon or rectum) and received one of two chemotherapeutic regimens after surgery (Regimen C: MMC 12 mg/m2 i.v. at operation day and 6 mg/m2 in every 2 months +UFT 600 mg/day p.o., D: the same dose of MMC + UFT 400 mg/day p.o.) randomly. 556 cases (colon carcinoma regimen C: 148, D: 185 cases, rectal carcinoma regimen C: 94, D: 129 cases) were evaluable at this presentation. Three-year-survival rate of histologically confirmed non-curatively resected colon carcinoma patients was higher in the group receiving regimen C than in regimen D. But no significant difference was found among the other groups.
authors.affiliation: 1st Dept. of Surgery, Tokushima University School of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Kunitomo
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Inokuchi
authors.forename: N
authors.initials: N
authors.lastname: Komi
authors.forename: T
authors.initials: T
authors.lastname: Hattori
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: O
authors.initials: O
authors.lastname: Abe
authors.forename: J
authors.initials: J
authors.lastname: Uchino
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D007564:Japan; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D014498:Uracil